Viral infections:

Indications for RUKOBIA:

In combination with other antiretroviral(s), for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.


Swallow whole. 600mg twice daily.


Not established.


Concomitant strong CYP3A4 inducers (eg, enzalutamide, carbamazepine, phenytoin, rifampin, mitotane, St. John's wort).


History of QTc interval prolongation. Preexisting cardiac disease. Immune reconstitution syndrome. Monitor LFTs in those with hepatitis B and/or C coinfection. Elderly. Pregnancy. Nursing mothers: not recommended.

Pharmacologic Class:

HIV-1 gp120-directed attachment inhibitor.


See Contraindications. May be antagonized by strong CYP3A4 inducers. May potentiate HCV direct-acting antivirals (eg, grazoprevir, voxilaprevir), statins drugs (eg, rosuvastatin, atorvastatin, fluvastatin, pitavastatin, simvastatin), ethinyl estradiol. Caution when concomitant drugs with a known risk for Torsade de Pointes.

Adverse Reactions:

Nausea, diarrhea, headache, abdominal pain, dyspepsia, fatigue, rash, sleep disturbance; elevated transaminases.

Generic Availability:


How Supplied:

Ext-rel tabs—60

Pricing for RUKOBIA

600mg tablet (Qty: 60)
Appx. price $7813